#16
|
|||
|
|||
Öèòàòà:
|
#17
|
||||
|
||||
Ìåòèëêîáàëàìèí (Âèòàìèí Á12) 1000 ìêã - Ñîëãàð
ôîëàò 400-800 ìêã - ñîëãàð è òî è äðóãîå â òå÷åíèå 1 ìåñ.; ïåðâûå 3-4 äíÿ ïðèíèìàåòå òîëüêî ìåòèëêîáàëàìèí; ðåêâèçèòû â ëè÷íîì ñîîáøåíèè
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#18
|
|||
|
|||
Öèòàòà:
Ñåãîäíÿ 4 äåíü ïîòðåáëåíèÿ B12, çàâòðà ïîäñîåäèíÿþ Á9. Áûë ó ãàñòðîýíòåðîëîãà, ïðèíèìàþ ìåòåîñïàçìèë, ðåáàãèò è ïåïñàí-ð. Ñäàâàë ãàñòðîïàíåëü: ãàñòðèí-17 ïîíèæåí (ãàñòðîýíòåðîëîã ñâÿçûâàåò ñ ïîâûøåííîé êèñëîòíîñòüþ = ðåôëþêñ-ýçîôàãèò), â òî æå âðåìÿ, îí ïîíèæàåòñÿ ïðè àòðîôèè àíòðàëüíîãî îòäåëà æåëóäêà (÷òî ó ìåíÿ ïî ðåçóëüòàòàì áèîïñèè è óêàçàíî = ñóáàòðîôè÷åñêèé õðîíè÷åñêèé ãàñòðèò àíòðàëüíîãî îòäåëà ñ ôîâåîëÿðíîé ãèïåðïëàçèåé) Ñïðàøèâàë ó ãàñòðîýíòåðîëîãà, íå ìîæåò ëè ôåððèòèí áûòü ñâÿçàí ñ îïóõîëåâûì ïðîöåññîì, îíà ÷òî-òî òàì äèôôåðåíöèðîâàëà, ìîë, òóò ïî òðàíñôåððèíó è ÎÆÑÑ âèäíî, ÷òî íåò, ìîë, â òàêîì ñëó÷àå è ñ-ðåàêòèâíûé áåëîê ïîâûøàåòñÿ. Äîïîì äàëà ìíå íàïðàâëåíèÿ íà ïèùåâûå àëëåðãåíû (íó íå áðåä ëè), è ïàðàçèòàðíàÿ ïàíåëü (ìäà...) Äîøåë äî êàðäèîëîãà, òà ìíå ïîíàçíà÷àëà êó÷ó àíàëèçîâ, õîëòåð è èçìåðåíèå ñóòî÷íîãî äàâëåíèÿ â òå÷åíèå òðåõ ñóòîê, ÝÌÍà (èñêëþ÷èòü íåâðîëîãè÷åñêóþ ñîñòàâëÿþùóþ ìûøå÷íîé ñëàáîñòè), ðåíòãåí ñ áàðèåì (èñêëþ÷èòü êðûæó ïèùåâîäíîãî îòâåðñòèÿ), ÓÇÄÑ ïî÷å÷íûõ àðòåðèé (äàâëåíèå åé íå ïîíðàâèëîñü 140x74 ïðè å¸ èçìåðåíèè). Èç àíàëèçîâ äàëà íàïðàâëåíèÿ íà ìèêðîàëüáèíóðèþ, ñâîáîäíûé è ñâÿçàííûé ãèäðîêñèïðîëèí (áîæå ó íàñ â ëàáàõ òàêîå íå äåëàþò), àãðåãàöèÿ òðîìáîöèòîâ (òîæå òà åù¸ ôèãíÿ), ãîìîöèñòåèí, ôàêòîð Âèëëåáðàíäà, âèòàìèí Ä, ïàðàòãîðìîí, ôîñôîð, NT-PRO-BNP. Íàïðàâèëè â êàðäèîëîãè÷åñêèé ïåðåäåëûâàòü ÝÕÎÊÃ, äåñêàòü âîò ïåðâàÿ ÝÕÎÊà ïðîëàïñ 2 ñòåïåíè, âòîðàÿ -1 ñòåïåíü (6 ìì ïðîòèâ 3ìì), ñåãîäíÿ ïåðåäåëàë, - 1 ñòåïåíü, ÝÌÍà òîæå ñäåëàë, íèêàêèõ äàííûõ çà ïàòîëîãèþ (íó åù¸ áû ÁÀÑ?!) Âîò äóìàþ äåëàòü ðåíòãåí èëè íåò, çà ïîëòîðà ìåñÿöà 20 Ìç óæå îáëó÷åíèÿ ïîëó÷èë. 5 àïðåëÿ ñíîâà äåëàþ ÔÃÄÑ (äà ÷òî æ ýòî òàêîå, íåóæåëè íåëüçÿ ñäåëàòü îäèí ÍÎÐÌÀËÜÍÛÉ ÔÃÄÑ?!?!?!) Ñîñòîÿíèå óãàñàíèÿ: ñèë íåò, àïïåòèò ïëàâàþùèé, òî õî÷ó íà ãðàíå áåçóìèÿ êóøàòü, òî âîîáùå íåò æåëàíèÿ. Òàõà çàäðàëà, ïîñòîÿííîå îùóùåíèå ñâîåãî ñåðäöåáèåíèÿ (íå, íó ÿ ñ÷èòàþ ñâîé ïóëüñ äàæå ïðè íîðìàëüíîé ×ÑÑ), áðîñàåò â ïîò, ïîñëå íî÷íîãî ïðîáóæäåíèÿ øîðòû âëàæíûå (äà ñïëþ â øîðòàõ è ÷òî òàì ïîäòåêàåò áëèí). È âîò åù¸ ÷òî áëèí, ãîâîðèò, íó áûòü ìîæåò åù¸ òàáëåòî÷êó ïðîãëîòèòü (êàïñóëüíàÿ ýíäîñêîïèÿ), ùîá ïîñìîòðåòü òîíêèé êèøå÷íèê, ìäàààààààààààà, íåóæåëè òàê äèôôåðåíöèðóþò ÐÀÊÎÂÓÞ ÈÍÒÎÊÑÈÊÀÖÈÞ (à ÷òî æå ýòî òàêîå, òàõè ñëàáîñòü, ïîòëèâîñòü?!) îò äðóãèõ, àä à íå æèçíü â îáùåì, ïðîñòèòå, íî êðèê äóøè [Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] |
#19
|
|||
|
|||
Îé, çàáûë ñêàçàòü, äåëàë àíàëèç íà ãåìîõðîìàòîç, íî îïÿòü æå íèêàêîé êëèíèêè íåò ïî-âèäèìîìó
|
#20
|
||||
|
||||
àíàëèç íà ãåìîõðîìàòîç íå ïîêàçàòåëåí, ãåòåðîçèðîòû ðåäêî äàþò ïåðåãðóçêó åñëè âîîáøå, ìíîæåñòâî åñëè íå âñå àíàëèçû - ÍÅ íóæíû! åñëè ñîáðàëèñü ÷òî-òî äåëàòü èç-ñïèñêà íàïèøèòå, ÷òî èìåííî ñêàçó ïî÷åìó áåññìûñëåííî; ãàñòðèí 17 ñíèæàåòñÿ ïðè àòðîôèè àíòðàëüíîãî îòäåëà èëè àíòðàëüíîãî + òåëà æåëóäêà
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#21
|
|||
|
|||
Öèòàòà:
|
#22
|
||||
|
||||
äàííûõ çà ÎÍÊÎ- íåò; âñå âàøè ñîìíåíèÿ è ñòðàõè èç-çà àòðîôè÷åñêîãî ãàñòðèòà, êîòîðûé âûçûâàåò â12 äåôèöèò, à çàäîëãî äî àíåìèçàöèè - âñ¸-÷òî óãîäíî îò ñëàáîñòè dî ïàðàíîéè
The affected patients may present with a variety of signs and symptoms ranging from weakness to severe manifestations such as paranoia (megaloblastic madness)...
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
|
#23
|
||||
|
||||
ëå÷åíèå äåôèöèòà æåëåçà, â12 è ôîëèåâîé, åñëè îò â12 âíóòðü åôôåêòà íåò, òîãäà â/ì The therapy with the supplementation of iron, folic acid and cobalamin is commonly recommended in the early stages prior to progression to PA. Oral vitamin B12 supplement is used since it has been shown 1% of free vitamin B12 can be absorbed in the small intestine via passive diffusion.93 However, in patients with neurological manifestations, parenteral administration of vitamin B12 is currently recommended.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#24
|
|||
|
|||
Öèòàòà:
|
#25
|
||||
|
||||
íè÷åãî íå äåëàòü - íå âèæó êóäà âàñ åòî ïðèâåäåò äèàãíîñòè÷åñêè, êàê ñïåöèàëèñò ïî ñâåðòûâàíèþ êðîâè (áîëåå 20 ñòàòåé â ðàçíûõ æóðíàëàõ ìèðà) - ïðÿìî âàì ãîâîðþ ó âàñ ñ íåé ïðîáëåì íåò
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#26
|
|||
|
|||
Öèòàòà:
 òàêîì ñëó÷àå ñ àíàëèçàìè ÿ ïîâðåìåíþ, ñåãîäíÿ õîëòåð ïîâåñèëè, 3 àïðåëÿ ïîâåñÿò äàâëåíèå, òàì æå ÓÇÄÑ ñîñóäîâ ïå÷åíè, à 5 ÔÃÄÑ. Ñêàæèòå ïîæàëóéñòà, ñòîèò ëè ìíå äåëàòü ðåíòãåí ñ áàðèåì, äîïîëíèòåëüíûå 3.5 Ìç ñ ó÷åòîì óæå ïîëó÷åííîé çà ïîëòîðà ìåñÿöà äîçû â 20 Ìç íå áóäåò ïàãóáíûì? Îïÿòü æå ïî òðàäèöèè, õî÷ó âàñ îòáëàãîäàðèòü, ðåêâèçèòû òå æå? |
#27
|
||||
|
||||
íåò, ðåíòãåí ñ áàðèåì íå íóæåí, íå âèæó ÷òî îí ìîæåò äàòü ïîëåçíîãî äèàãíîñòè÷åñêè, ðåêâèçèòû ïðåæíèå
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#28
|
|||
|
|||
Äîáðîå âðåìÿ ñóòîê, óâ. Âàäèì Âàëåðüåâè÷.
Ïðîøëî íåìàëî ìåñÿöåâ ñ ïîñëåäíåãî ìîåãî ïîñåùåíèÿ è ñ îêîí÷àíèåì êóðñà âàìè íàçíà÷åííîãî, ïëþñ-ìèíóñ ñîñòîÿíèå ìî¸ íà ïðîòÿæåíèè ýòîãî âðåìåíè íå ìåíÿëîñü: áîëè ñîõðàíÿþòñÿ, ñëàáîñòü, òàõèêàðäèÿ, ýòî óæå ñòàëî ÷àñòüþ ìåíÿ. Ðåøèë íàáðàòüñÿ âîëè è ñäàòü àíàëèçû ïîâòîðíî. Ôåððèòèí ñ òåõ ïîð âûðîñ íà 100 åäèíèö. Íå ìîãëè áû âû ïîäñêàçàòü, êóäà äâèãàòüñÿ äàëüøå â äèàãíîñòè÷åñêîì ñâîåì ïîèñêå. Çàðàíåå áëàãîäàðþ |
#29
|
||||
|
||||
ôåððèòèí - îñòðîôàçîâûé áåëîê è âûäåëÿåòñÿ ïðè ïîâðåæäåíèè ïå÷åíè, åñëè âåéï íà âàøó ïå÷åíü äåéñòâóåò õóæå, ÷åì ñèãàðåòû, òî íàêîïëåíèå æèðà â ïå÷åíî÷íûõ êëåòêàõ âåäåò ê ïîâûøåíèþ ôåððèòèíà
E-cigarettes have been linked to liver damage in several ways, according to research done in the lab and animals (16). In comparison to control mice, rats fed a western diet (NASH model) and exposed to e-cigarettes had significantly higher levels of hepatic lipid accumulation and hepatocyte mortality (47). Oxidative stress and necrosis, as well as changes in cholesterol and fat metabolism and circadian clock networks in the liver, are all related to the adverse effects of electronic cigarettes on the development of steatosis (47).
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#30
|
|||
|
|||
Öèòàòà:
|